AstraZeneca is acquiring FibroGen China assets, which was approved by the China State Administration for Market Regulation.
2 reports, 1 independent
Updated Aug 18
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca is acquiring FibroGen China assets, which was approved by the China State Administration for Market Regulation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
FibroGen (United States)
company in San Francisco, United States
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireFibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO,
- GlobeNewswireFibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a